Results 71 to 80 of about 144,610 (311)

Risk Prediction Models for Recurrence After Curative Treatment of Early‐Stage or Locally Advanced Lung Cancer: A Systematic Review

Aging and Cancer, EarlyView.
This systematic review synthesizes prognostic models for survival and recurrence in resected non‐small cell lung cancer. While many models demonstrate moderate to good discrimination, few are externally validated and reporting quality is variable, limiting clinical applicability and highlighting the need for robust, transparent model development ...
Evangeline Samuel, S. Tissera, E. Paul, J. Zalcberg, R. G. Stirling   +4 more
wiley   +1 more source

Neoadjuvant Therapy [PDF]

Advances in Surgery, 2020
Kristin N. Kelly, Francisco I. Macedo, Nipun B. Merchant   +2 more
openaire   +2 more sources

Advances in the use of Radiomics and Pathomics for predicting the efficacy of neoadjuvant therapy in tumors

Translational Oncology
Neoadjuvant therapy is widely used for treating malignant tumors, but its efficacy varies among patients. Currently, tools or biomarkers for early and accurate evaluation of the efficacy of neoadjuvant therapy are lacking.
Jiayi Wang, Jiahui Dai, Yangxi Cheng, Xirui Wang, Rui Deng, Huiyong Zhu   +5 more
doaj   +1 more source

Neoadjuvant Treatment Strategies in Resectable Pancreatic Cancer

, 2021
Complete surgical resection is the cornerstone of curative therapy for resectable pancreatic adenocarcinoma. Upfront surgery is the gold standard, but it is rarely curative.
Thierry Conroy, Michel Ducreux, Aurélien Lambert, Lilian Schwarz   +3 more
core   +1 more source

Tumor‐Derived LAMB3 Drives Immunosuppressive LRRC15+ Fibroblast Formation During Pancreatic Ductal Adenocarcinoma Development

Advanced Science, EarlyView.
A single‐cell atlas of pancreatic ductal adenocarcinoma development reveals progressive ductal‐fibroblast‐immune crosstalk. Tumor‐derived LAMB3 drives the formation of immunosuppressive LRRC15+ fibroblasts through the ITGB1/FAK/MAPK/FOSL2 signaling. Glycolytic reprogramming upregulates LAMB3 and correlates with LRRC15+ fibroblast enrichment.
Xuqing Shi, Hangqi Liu, Jianru Sun, Xiaoding Liu, Xinping Jv, Longyun Chen, Yuhan Zhang, Hui Zhang, Xudong Xing, Ruiyu Li, Xinyi Ke, Jun Wang, Xianglin Yin, Bohan Liu, Qixian Liu, Yuan Wang, Junliang Lu, Shiyi Liu, Junyi Pang, Yumeng Cai, Menghua Dai, Fan Bai, Huanwen Wu, Zhiyong Liang   +23 more
wiley   +1 more source

Recent Progress in the Neoadjuvant Treatment Strategy for Locally Advanced Esophageal Cancer

, 2021
Neoadjuvant therapies, primarily chemotherapy and chemoradiotherapy, are able to improve the overall survival (OS) in patients with locally advanced resectable esophageal cancer (EC) based on the results of several randomized clinical trials.
Sicong Hou, Yanbing Ding, Qinglei Hang, Ziyin Pan, Xin Hao   +4 more
core   +1 more source

Genome‐Wide In Vivo RNAi Screening Identifies HOXD4 as a Tumor Metastasis Suppressor in Colorectal Cancer

Advanced Science, EarlyView.
Metastasis remains a major challenge in colorectal cancer. Using an in vivo shRNA screening system, this study identifies Homeobox D4 as a key metastasis suppressor. Reduced Homeobox D4 expression is associated with aggressive tumor features. Functional and mechanistic analyses show that it inhibits epithelial‐mesenchymal transition by repressing ...
Zhi‐hua Ye, Wen‐jing Luo, Lu Li, Wen‐di Shuai, Ling Zhou, You‐fa Duan, Xue Chen, Jun‐kai Zhang, Wenlin Huang, Ran‐yi Liu   +9 more
wiley   +1 more source

Placement of a self-expandable metallic stent as a bridge to surgery for large bowel obstruction induced by effective neoadjuvant therapy: report of three cases

Surgical Case Reports, 2018
Background Self-expandable metallic stent placement is a widely performed palliative procedure or bridge to surgery for obstructive colorectal cancer. However, the feasibility of this procedure for large bowel obstruction induced by effective neoadjuvant
Fumihiko Ando, Akihisa Matsuda, Masao Miyashita, Satoshi Matsumoto, Nobuyuki Sakurazawa, Youichi Kawano, Hiroshi Yoshida   +6 more
doaj   +1 more source

Radio-chemotherapy as a preoperative treatment for advanced rectal cancer. Evaluation of down-staging and morbidity [PDF]

, 2002
Background: The standard therapy for patients with clinically resectable rectal cancer is generally considered to be surgery, If the patient is diagnosed with advanced disease, postoperative radiochemotherapy (RCT) is usually recommended. In our study we
Wilkowski, R., Schaffer, Pamela Manuela, Thoma, M., Dühmke, Eckhart, Schaffer, Moshe   +4 more
core   +1 more source

Pharmacologic Modulation of ARID3A with Rimegepant Reactivates Type I Interferon Signaling and Sensitizes Triple‐Negative Breast Cancer to PD‐1 Blockade

Advanced Science, EarlyView.
This study identifies ARID3A as a key immunosuppressive transcription factor in TNBC. Its inhibition activates the type I IFN pathway, boosting CD8+ T cell infiltration and sensitizing tumors to anti‐PD‐1. The FDA‐approved migraine drug Rimegepant targets ARID3A, enhances immunotherapy efficacy in preclinical models, and establishes a druggable axis to
Teng Zhou, Yifei Zhu, Cheng Zeng, Jinlu Han, Huiying Huang, Doudou Li, Mingxi Lin, Yizi Jin, Qin Guo, Yuxin Yan, Xinhui Mao, Yifei Zhou, Jian Zhang   +12 more
wiley   +1 more source